Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
To study the efficacy of everolimus combined with temozolomide as first-line treatment in
advanced gastroenteropancreatic neuroendocrine carcinoma with a Ki67 of 20-55%, measured as
disease control rate (non-progressive disease) at 6 months.
Phase:
Phase 2
Details
Lead Sponsor:
Haukeland University Hospital
Collaborators:
Aarhus University Hospital Copenhagen University Hospital, Denmark Rigshospitalet, Denmark Sahlgrenska University Hospital, Sweden Skane University Hospital Ullevaal University Hospital Uppsala University Hospital